Sputnik V Vaccine's International Scientific Advisory Board Established

The National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) announced on January 18, 2021, creating an International Scientific Advisory Board on the Sputnik V vaccine. Leading scientists in virology, microbiology, genetics, and biotechnology from Argentina, Croatia, France, Germany, India, Russia, Sweden, UK, and the USA, representing top research and medical centers, have joined the Board, stated a press release.

Kirill Dmitriev, CEO of the RDIF, said: "scientific exchange has become especially in demand in connection with the pandemic of the new coronavirus infection, a global problem that has stimulated the unification of all global research potential. We are grateful to all the experts who accepted our offer to join the Council. International partnership, including the coronavirus vaccine, is the key to ultimate victory and proves once again that the noble goal of saving lives has no boundaries."

The Sputnik V (Gam-COVID-Vac) is an adenoviral-based vaccine against the SARS-CoV-2 coronavirus. Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.

The Sputnik V vaccine has been registered in Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, and Paraguay.